The US FDA approved aripiprazole LAI in February 2013 for the treatment of schizophrenia. In another retrospective study of hospital re-admission rates, LAIs were significantly associated with a 16 % reduced risk of re-admission after 60 days compared to oral antipsychotic medications.A retrospective study of adherence to oral or LAIs in schizophrenia patients six months after hospital discharge showed that nonadherence was lower in the LAI cohort, and fewer patients were re-hospitalized (significant only for second-generation LAIs).Interestingly, a subgroup analysis revealed that LAIs were significantly better at reducing hospital readmission rates when the publication year was ≥2010 and when the study had an academic sponsor. In a meta-analysis of prospective and retrospective studies, LAIs significantly reduced the rate of hospital re-admission and treatment discontinuation compared to oral antipsychotics.However, there were no significant differences in hospitalization rate or non-adherence rates between the LAI and oral antipsychotic medication groups. When comparing the efficacy and safety of LAIs and second-generation oral antipsychotics, there was a significantly lower relapse rate, a longer time to relapse, and fewer hospital days favouring LAIs. , ĮVIDENCE FOR USE OF LONG ACTING INJECTABLES (LAIs) This is despite that LAI antipsychotics have been proven to have efficacy that is non-inferior to oral formulations in most long-term studies. This is also particularly true in psychotic patients who are in remission.Īlthough there has been an increase in the availability of LAI formulations, they are currently underutilized. , Therefore, there is considerable interest in transitioning patients from oral medication to long-acting injectable (LAI) antipsychotics. This article covers the psychopharmacology of Aripiprazole LAIs.Īntipsychotic nonadherence is common in schizophrenia with rates high (44% to 75%) across all stages of the disease, from patients with first-episode psychosis to patients with chronic schizophrenia. Aripiprazole long-acting injections (LAIs) come in two forms – Abilify Maintena and Aristada.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |